A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

• ClinicalTrials.gov Identifier: NCT01297413
• Recruitment Status: Completed
• First Posted: February 16, 2011
• Last Update Posted: December 3, 2018
• Sponsor: Stemedica Cell Technologies, Inc.
• Collaborators: University of California, San Diego; Mercy Gilbert Medical Center at AZ; Chandler Regional Medical Center at Chandler AZ; UCI Medical Center
• Information provided by (Responsible Party): Stemedica Cell Technologies, Inc.

Study Description

Brief Summary:

The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.

Condition or disease	Intervention/treatment	Phase
Ischemic Stroke	Biological: Allogeneic adult mesenchymal bone marrow stem cells	Phase 1; Phase 2

Detailed Description:

Stroke remains a major global healthcare problem. Recent data compiled by the American Heart Association (AHA) for 2008 show that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. Among adults age 20 and older, the estimated prevalence of stroke in 2005 was 5.8 million in the United States, resulting in >150,000 deaths annually, with 4.8 million stroke survivors alive today. Stroke ranks as the country's third leading cause of death, behind only cancer and heart disease. The only approved treatments of acute ischemic stroke involve restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy. Following the completion of a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy.

Allogeneic mesenchymal stem cells have been used in a number of clinical trials for different indications demonstrated the safety of allogeneic mesenchymal stem cell treatment. In addition to their ability to differentiate into multiple different cell types that would be contributory to the recovery and repair of the brain by replacing destroyed cells, mesenchymal stem cells also secrete angiogenins, cytokines and trophic factors that can support and stimulate multiple other cell types. The cascade of cellular events following the release of these cytokines and trophic factors would also potentially lead to beneficial effects by restoring blood supply, by rescuing cells at risk, and by stimulating the remaining cell populations to repair and propagate new cells and synaptic connections.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 38 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke
• Study Start Date: February 2011
• Actual Primary Completion Date: September 2017
• Actual Study Completion Date: November 15, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Stem cells; All subjects will receive allogeneic adult mesenchymal bone marrow stem cells	Biological: Allogeneic adult mesenchymal bone marrow stem cells; Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells

Outcome Measures

Primary Outcome Measures :

1. The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period. [ Time Frame: 12 month ]
   The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations.

Secondary Outcome Measures :

1. National Institutes of Health Stroke Scale Score. [ Time Frame: 12 months ]
   The change from the baseline in National Institutes of Health Stroke Scale score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available:
2. Mini Mental Status Exam score. [ Time Frame: 12 month ]
   The change from the baseline in Mini Mental Status Exam score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available.
3. Barthel Index Score. [ Time Frame: 12 month ]
   The change from the baseline in Barthel Index score at 1, 3, 6, 9, 12 months post-treatment, as available.
4. The Geriatric Depression Scale Score. [ Time Frame: 12 month ]
   The change from baseline in the Geriatric Depression Scale score at 1, 3, 6, 9, 12 months post-treatment, as available.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Clinical diagnosis of ischemic stroke for longer than 6 months
• Brain CT/MRI scan at initial diagnosis and at enrollment consistent with ischemic stroke
• No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment
• NIHSS score between 6-20
• Life expectancy greater than 12 months
• Prior to treatment patient received standard medical care for the secondary prevention of ischemic stroke
• Adequate organ function as defined by the following criteria:

Exclusion Criteria:

• History of uncontrolled seizure disorder
• History of cancer within the past 5 years.
• History of cerebral neoplasm
• Positive for hepatitis B, C or HIV
• Myocardial infarction withing six months of study entry
• Findings on baseline CT suggestive of subarachnoid or intracerebral hemorrhage within past 12 months.
• Allergies to Bovine or Porcine products

Contacts and Locations

Locations

United States, Arizona

Mercy Gilbert and Chandler Medical Center

Gilbert, Arizona, United States, 85224

United States, California

University of California Irvine Department of Neurology

Orange, California, United States, 92868

University of California San Diego Division of Neurological Surgery

San Diego, California, United States, 92123

Sponsors and Collaborators

Stemedica Cell Technologies, Inc.

University of California, San Diego

Mercy Gilbert Medical Center at AZ

Chandler Regional Medical Center at Chandler AZ

UCI Medical Center

Investigators

• Study Director: Lev Verkh, PhD; Stemedica Cell Technologies, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019 Oct;50(10):2835-2841. doi: 10.1161/STROKEAHA.119.026318. Epub 2019 Sep 9.

• Responsible Party: Stemedica Cell Technologies, Inc.
• ClinicalTrials.gov Identifier: NCT01297413
• Other Study ID Numbers: STEM 101-M
• First Posted: February 16, 2011
• Last Update Posted: December 3, 2018
• Last Verified: November 2018

Keywords provided by Stemedica Cell Technologies, Inc.:

allogeneic; adult; stem; cells; stroke; ischemic

Additional relevant MeSH terms:

Stroke; Ischemic Stroke; Cerebral Infarction; Ischemia; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Brain Infarction; Brain Ischemia; Infarction; Necrosis